Literature DB >> 29485558

Robin Sequence: Continuing Heterogeneity in Nomenclature and Diagnosis.

Daan P F van Nunen1, Marie-José H van den Boogaard2, Corstiaan C Breugem1.   

Abstract

OBJECTIVE: Heterogeneity in both nomenclature and diagnostic criteria has hindered the interpretation of research into the congenital condition most widely known as (Pierre) Robin syndrome or sequence. In 2009, the discussion regarding its diagnosis and nosology was reopened to converge on a uniform eponym and standard set of diagnostic criteria. The objective of this study was to assess the impact of this debate.
MATERIALS AND METHODS: This is a retrospective review of the nomenclature and diagnostic criteria employed in studies about this condition that were indexed in the MEDLINE literature database (PubMed) and published during 2009 to 2016.
RESULTS: A total of 440 studies were retrieved of which the majority used the eponyms "Pierre Robin sequence" (62.0%) or "Robin sequence" (23.4%). During the study period, there was a significant shift toward the use of "sequence" in preference over "syndrome." Only 71.4% of studies mentioned their criteria for diagnosis, which remained heterogeneous throughout the study period.
CONCLUSION: Since 2009, the debate has not produced a consensus eponym and standard diagnosis. This is unfortunate given the enduring controversies over the optimal management of a condition associated with a high morbidity and mortality. A renewed effort is needed to arrive at a workable consensus to enhance the retrievability of relevant literature and facilitate the interpretation of outcome studies.

Entities:  

Mesh:

Year:  2018        PMID: 29485558     DOI: 10.1097/SCS.0000000000004361

Source DB:  PubMed          Journal:  J Craniofac Surg        ISSN: 1049-2275            Impact factor:   1.046


  1 in total

1.  Understanding the Spectrum of Treatment Options for Infants With Pierre Robin Sequence and Airway Obstruction.

Authors:  Joanna E MacLean
Journal:  J Clin Sleep Med       Date:  2019-03-15       Impact factor: 4.062

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.